NasdaqGS:SRPT

Stock Analysis Report

Executive Summary

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases.


Snowflake Analysis

Exceptional growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Sarepta Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SRPT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.3%

SRPT

4.7%

US Biotechs

7.2%

US Market


1 Year Return

-19.7%

SRPT

1.8%

US Biotechs

-10.4%

US Market

Return vs Industry: SRPT underperformed the US Biotechs industry which returned 1.8% over the past year.

Return vs Market: SRPT underperformed the US Market which returned -10.4% over the past year.


Shareholder returns

SRPTIndustryMarket
7 Day6.3%4.7%7.2%
30 Day-13.9%-3.5%-12.6%
90 Day-23.7%-5.4%-19.4%
1 Year-19.7%-19.7%2.6%1.8%-8.5%-10.4%
3 Year242.2%242.2%14.0%11.1%15.8%8.3%
5 Year580.9%580.9%-3.6%-7.9%35.8%21.0%

Price Volatility Vs. Market

How volatile is Sarepta Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Sarepta Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: SRPT ($98.52) is trading below our estimate of fair value ($315.9)

Significantly Below Fair Value: SRPT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: SRPT is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SRPT is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SRPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SRPT is overvalued based on its PB Ratio (9.1x) compared to the US Biotechs industry average (2.6x).


Next Steps

Future Growth

How is Sarepta Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?

59.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SRPT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: SRPT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: SRPT's is expected to become profitable in the next 3 years.

Revenue vs Market: SRPT's revenue (37.2% per year) is forecast to grow faster than the US market (7.2% per year).

High Growth Revenue: SRPT's revenue (37.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: SRPT's Return on Equity is forecast to be very high in 3 years time (46.2%).


Next Steps

Past Performance

How has Sarepta Therapeutics performed over the past 5 years?

-28.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SRPT is currently unprofitable.

Growing Profit Margin: SRPT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SRPT is unprofitable, and losses have increased over the past 5 years at a rate of -28.6% per year.

Accelerating Growth: Unable to compare SRPT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SRPT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).


Return on Equity

High ROE: SRPT has a negative Return on Equity (-87.4%), as it is currently unprofitable.


Next Steps

Financial Health

How is Sarepta Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: SRPT's short term assets ($1.5B) exceed its short term liabilities ($264.8M).

Long Term Liabilities: SRPT's short term assets ($1.5B) exceed its long term liabilities ($739.9M).


Debt to Equity History and Analysis

Debt Level: SRPT's debt to equity ratio (83.3%) is considered high.

Reducing Debt: SRPT's debt to equity ratio has increased from 2.6% to 83.3% over the past 5 years.


Balance Sheet

Inventory Level: SRPT has a low level of unsold assets or inventory.

Debt Coverage by Assets: SRPT's debt is covered by short term assets (assets are 2.2x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SRPT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if SRPT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Sarepta Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SRPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SRPT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SRPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SRPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SRPT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Doug Ingram (56yo)

2.67s

Tenure

US$1,433,872

Compensation

Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 28, 2017. Mr. Ingram serves as Director of Relay Therapeutics, ...


CEO Compensation Analysis

Compensation vs Market: Doug's total compensation ($USD1.43M) is below average for companies of similar size in the US market ($USD7.28M).

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Douglas Ingram
President2.67yrsUS$1.43m0.51% $38.9m
Sandesh Mahatme
Executive VP7.25yrsUS$4.22m0.054% $4.2m
David Howton
Executive VP7.25yrsUS$3.13m0.032% $2.5m
Alexander Cumbo
Executive VP & Chief Commercial Officer3.42yrsUS$3.12m0.0068% $522.6k
Gilmore O'Neill
Executive VP of R&D and Chief Medical Officer1.67yrsUS$6.67m0.0095% $726.4k
William Ciambrone
Executive Vice President of Technical Operations0.25yrno datano data
Ian Estepan
Senior VP of Corporate Affairs & Chief of Staff2.17yrsno datano data
Diane Berry
Senior Vice President of Global Health Policy and Government & Patient Affairs0.42yrno datano data
Joan Nickerson
Senior Vice President of Human Resources0.42yrno datano data
Louise Rodino-Klapac
Senior Vice President of Gene Therapy1yrno datano data

1.9yrs

Average Tenure

54yo

Average Age

Experienced Management: SRPT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Douglas Ingram
President2.67yrsUS$1.43m0.51% $38.9m
John Martin
Director0.17yrno datano data
M. Behrens
Chairwoman4.83yrsUS$502.15k0.17% $13.2m
Hans Wigzell
Chairman of Corporate Strategy Board & Non-Employee Directorno dataUS$467.02k0.013% $993.8k
Beverly Davidson
Member of Strategic & Scientific Advisory Board4.58yrsno datano data
Mary Gray
Independent Director1.25yrsUS$731.38k0.0013% $101.9k
Louis Kunkel
Member of Strategic & Scientific Advisory Board4.58yrsno datano data
Claude Nicaise
Non-Employee Director4.67yrsUS$464.51k0.0070% $534.1k
Kenneth Fischbeck
Member of Strategic & Scientific Advisory Board3yrsno datano data
Matthew Wood
Member of Strategic & Scientific Advisory Board3yrsno datano data

3.0yrs

Average Tenure

66.5yo

Average Age

Experienced Board: SRPT's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.1%.


Top Shareholders

Company Information

Sarepta Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Sarepta Therapeutics, Inc.
  • Ticker: SRPT
  • Exchange: NasdaqGS
  • Founded: 1980
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$7.663b
  • Shares outstanding: 77.78m
  • Website: https://www.sarepta.com

Number of Employees


Location

  • Sarepta Therapeutics, Inc.
  • 215 First Street
  • Suite 415
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SRPTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 1997
AB3ADB (Deutsche Boerse AG)YesCommon StockDEEURJun 1997
0L35LSE (London Stock Exchange)YesCommon StockGBUSDJun 1997
AB3ABRSE (Berne Stock Exchange)YesCommon StockCHCHFJun 1997

Biography

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51, for the treatment of duchenne muscular dystrophy (DMD); and VYONDYS 53 for the treatment of DMD in patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. Its products pipeline include Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene; SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD, micro-dystrophin gene therapy to treat peripheral neuromuscular diseases; SRP-9003, a gene therapy program for various types of limb-girdle muscular dystrophies; and LYS-SAF 302, a gene therapy program, which is in Phase 2/3 clinical trial to treat mucopolysaccharidosis type IIIA. The company has collaboration agreements with Nationwide Children’s Hospital to advance micro-dystrophin gene therapy program under the research and license option agreement; and GALGT2, a gene therapy program for the treatment of neuromuscular related disorders. In addition, it has a research agreement with Duke University to advance gene editing CRISPR/Cas9 technology for restoring dystrophin expression; a license and collaboration agreement with Lysogene S.A., a gene therapy company for the treatment of orphan diseases of the central nervous system; license and collaboration agreement with Genethon to develop micro-dystrophin gene therapy products for the treatment of DMD; and a collaboration and license agreement with StrideBio, Inc. to develop in vivo adeno-associated virus based therapies. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/31 00:30
End of Day Share Price2020/03/30 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.